Bristol-Myers Squibb is committed to helping appropriate patients get access to our medications by providing access and reimbursement support services.

This information is intended for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.

MY BMS CASES

LOG IN

CREATE ACCOUNT

OPDIVO® (nivolumab) and YERVOY® (ipilimumab) Regimen

INDICATION

OPDIVO, in combination with YERVOY, is indicated for the treatment of patients with unresectable or metastatic melanoma.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Billing and Diagnostic Codes icon

Billing and
Diagnosis Codes

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol-Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Reimbursement and Coding Guide for OPDIVO


Filter by keyword Clear Filter
Type a keyword to find a specific HCPCS, CPT, NDC or ICD-10 code
Healthcare Common Procedure Coding System (HCPCS) Codes1 Issued by CMS
OPDIVO
J9299

COPY

Injection, nivolumab, 1 mg

Effective January 1, 2017, providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.2

YERVOY
J9228

COPY

Injection, ipilimumab, 1 mg

Effective January 1, 2017, providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.2

Current Procedural Terminology (CPT)3,†
OPDIVO
96413

COPY

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

YERVOY
96417

COPY

Chemotherapy administration, IV infusion; each additional sequential infusion (different substance/drug), up to 1 hour (list separately in addition to code for primary procedure). (Use 96417 in conjunction with 96413)

96415

COPY

Chemotherapy administration, IFV infusion; each additional hour (list separately in addition to code for primary procedure). (Report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour increments)

National Drug Codes (NDC)4,5 Issued by the FDA

Note:Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.

OPDIVO
00003-3772-11

COPY

40 mg/4 mL (10 mg/mL) single-dose vial

00003-3774-12

COPY

100 mg/10 mL (10 mg/mL) single-dose vial

YERVOY
00003-2327-11

COPY

One 50-mg vial (5 mg/mL), single-use vial

00003-2328-22

COPY

One 200-mg vial (5 mg/mL), single-use vial

International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)6

C43

COPY

Malignant melanoma of skin

C43.0

COPY

Malignant melanoma of lip

C43.1

COPY

Malignant melanoma of eyelid, including canthus

C43.10

COPY

Malignant melanoma of unspecified eyelid, including canthus

C43.11

COPY

Malignant melanoma of right eyelid, including canthus

C43.12

COPY

Malignant melanoma of left eyelid, including canthus

C43.2

COPY

Malignant melanoma of ear and external auricular canal

C43.20

COPY

Malignant melanoma of unspecified ear and external auricular canal

C43.21

COPY

Malignant melanoma of right ear and external auricular canal

C43.22

COPY

Malignant melanoma of left ear and external auricular canal

C43.3

COPY

Malignant melanoma of other and unspecified parts of face

C43.30

COPY

Malignant melanoma of unspecified part of face

C43.31

COPY

Malignant melanoma of nose

C43.39

COPY

Malignant melanoma of other parts of face

C43.4

COPY

Malignant melanoma of scalp and neck

C43.5

COPY

Malignant melanoma of trunk

C43.51

COPY

Malignant melanoma of anal skin

C43.52

COPY

Malignant melanoma of skin of breast

C43.59

COPY

Malignant melanoma of other part of trunk

C43.6

COPY

Malignant melanoma of upper limb, including shoulder

C43.60

COPY

Malignant melanoma of unspecified upper limb, including shoulder

C43.61

COPY

Malignant melanoma of right upper limb, including shoulder

C43.62

COPY

Malignant melanoma of left upper limb, including shoulder

C43.7

COPY

Malignant melanoma of lower limb, including hip

C43.70

COPY

Malignant melanoma of unspecified lower limb, including hip

C43.71

COPY

Malignant melanoma of right lower limb, including hip

C43.72

COPY

Malignant melanoma of left lower limb, including hip

C43.8

COPY

Malignant melanoma of overlapping sites of skin

C43.9

COPY

Malignant melanoma of skin, unspecified

C21

COPY

Malignant neoplasm of anus and anal canal

C21.0

COPY

Malignant neoplasm of anus, unspecified

C21.1

COPY

Malignant neoplasm of anal canal

C51

COPY

Malignant neoplasm of vulva

C51.0

COPY

Malignant neoplasm of labium majus

C51.1

COPY

Malignant neoplasm of labium minus

C51.2

COPY

Malignant neoplasm of clitoris

C51.9

COPY

Malignant neoplasm of vulva, unspecified

C52

COPY

Malignant neoplasm of vagina

C57

COPY

Malignant neoplasm of other and unspecified female genital organs

C57.7

COPY

Malignant neoplasm of other specified female genital organs

C57.8

COPY

Malignant neoplasm of overlapping sites of female genital organs

C57.9

COPY

Malignant neoplasm of female genital organ, unspecified

C60

COPY

Malignant neoplasm of penis

C60.0

COPY

Malignant neoplasm of prepuce

C60.1

COPY

Malignant neoplasm of glans penis

C60.8

COPY

Malignant neoplasm of overlapping sites of penis

C60.9

COPY

Malignant neoplasm of penis, unspecified

C63

COPY

Malignant neoplasm of other and unspecified male genital organs

C63.0

COPY

Malignant neoplasm of epididymis

C63.00

COPY

Malignant neoplasm of unspecified epididymis

C63.01

COPY

Malignant neoplasm of right epididymis

C63.02

COPY

Malignant neoplasm of left epididymis

C63.1

COPY

Malignant melanoma of spermatic cord

C63.10

COPY

Malignant neoplasm of unspecified spermatic cord

C63.11

COPY

Malignant neoplasm of right spermatic cord

C63.12

COPY

Malignant neoplasm of left spermatic cord

C63.2

COPY

Malignant neoplasm of scrotum

C63.7

COPY

Malignant neoplasm of other specified male genital organs

C63.8

COPY

Malignant neoplasm of overlapping sites of male genital organs

C63.9

COPY

Malignant neoplasm of male genital organ, unspecified

Z51.12

COPY

Encounter for antineoplastic immunotherapy

If infusion for antineoplastic immunotherapy is the only reason for the patient encounter, physicians and hospitals may report ICD-10-CM code “Z51.12 Encounter for antineoplastic immunotherapy” as the primary diagnosis.

OPDIVO and YERVOY may be purchased through the distributors listed below.

Physician offices

Specialty Distributor Phone Orders Website
Cardinal Health Specialty Pharmaceutical Distribution 1-877-453-3972 Monday-Friday,
7 AM-7 PM CT
(24-hour emergency on call)
https://specialtyonline.cardinalhealth.com
CuraScript Specialty Distribution 1-866-433-3589 Monday-Friday,
8:30 AM-7 PM ET
https://www.curascriptsd.com
McKesson Specialty Health 1-800-482-6700 Monday-Friday,
7 AM-7 PM CT
https://mscs.mckesson.com
Oncology Supply 1-800-633-7555 Monday-Thursday,
8 AM-7:30 PM CT;
Friday, 8 AM-7 PM CT
https://www.oncologysupply.com

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain OPDIVO and YERVOY from the distributors listed above.

Hospitals and Infusion Centers

Specialty Distributor Phone Orders Fax Orders and Website
ASD Healthcare 1-800-746-6273
Monday-Thursday,
7:30 AM-6:30 PM CT;
Friday, 7 AM-6 PM CT
(24-hour emergency on call)
1-800-547-9413 https://www.asdhealthcare.com
Cardinal Health Specialty Pharmaceutical Distribution 1-866-677-4844
Monday-Friday,
7 AM-6 PM CT
(24-hour emergency on call)
1-888-345-4916 https://orderexpress.cardinalhealth.com
DMS Pharmaceutical Group, Inc. 1-877-788-1100
Monday-Friday,
7:30 AM-6 PM CT
1-847-518-1105
www.dmspharma.com
McKesson Plasma and Biologics 1-877-625-2566
Monday-Friday,
8 AM-6:30 PM CT
1-888-752-7626
https://connect.mckesson.com
Smith Medical Partners 1-800-292-9653
Monday-Thursday,
8 AM-6 PM CT;
Friday, 8 AM-4:30 PM CT
1-630-227-9220
www.smpspecialty.com

Above information is accurate as of 01/17.

The OPDIVO and YERVOY distribution program includes extended payment terms to Bristol-Myers Squibb authorized OPDIVO and YERVOY distributors. Healthcare providers and institutions should contact their OPDIVO and YERVOY distributor to understand specific payment terms that may be available to them from their distributor.

 
 


Coding for OPDIVO and YERVOY Regimen is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding information provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding information and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

CPT codes and descriptions only are ©2015 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

References:

  1. American Medical Association. 2017 HCPCS Level II. Professional ed. Chicago, IL: American Medical Association; 2017.
  2. Centers for Medicare & Medicaid Services. MLN Matters, Number MM9603 Revised. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9603.pdf. Revised June 10, 2016. Accessed January 12, 2017.
  3. American Medical Association. Current Procedural Terminology 2017. Professional ed. Chicago, IL: American Medical Association; 2016.
  4. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  5. YERVOY [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  6. American Medical Association. 2017 ICD-10-CM: The Complete Official Codebook. Chicago, IL: American Medical Association; 2016.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol-Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Support Center icon
8 am to 8 pm ET,
Monday - Friday
Schedule a Call iconSchedule a Call

Schedule a call from a Care Coordinator

Request a Visit icon Request a Visit

Request a visit from a BMS Access & Reimbursement Manager

 
BMS Logo

©2018 Bristol-Myers Squibb Company. All rights reserved. Access Support and Access Support logo are registered trademarks of Bristol-Myers Squibb Company.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Statement. The coding, coverage, and payment information contained within this website is current as of 01/17.

7356US1605612-01-01 01/17